Training of the personnel of a spa center to provide a therapeutic education program

2018 ◽  
Vol 33 (S1) ◽  
pp. 103-103
Author(s):  
K Dubourg
2018 ◽  
Vol 25 (6) ◽  
pp. 1523-1525 ◽  
Author(s):  
Marine Deppenweiler ◽  
Marc Debled ◽  
Jean-Luc Robquin ◽  
Barbara Lortal-Canguilhem

Trastuzumab is a monoclonal antibody used to treat human epidermal growth receptor 2 positive (HER2+) breast cancers either by itself or in combination with other chemotherapy medication. Marketing authorization was granted for a subcutaneous form of the antibody in 2014. In this case report, we discuss our experience with a patient who took part in a therapeutic education program on self-administration of trastuzumab. We demonstrate that these types of self-administered injections are not only possible but also are toxicity-free. Based on the tolerance data and our patient’s experience, we propose that the current regulations be relaxed regarding the availability of trastuzumab subcutaneous form in order to develop a cheaper “city scheme,” i.e. self-administered injections.


2012 ◽  
Vol 15 (7) ◽  
pp. A552
Author(s):  
N. Costa ◽  
H. Derumeaux-Burel ◽  
C. Canivet ◽  
F. Ory ◽  
C. Brefel-Courbon ◽  
...  

2012 ◽  
Vol 55 (1) ◽  
pp. 306
Author(s):  
P.H. Carpentier ◽  
B. Satger ◽  
M. Barrellier ◽  
C. Menez ◽  
J. Kubina ◽  
...  

2015 ◽  
Vol 114 (2) ◽  
pp. S28-S29
Author(s):  
Fabrice Camou ◽  
Arnaud Alessandrin ◽  
Eva Toussaint ◽  
Fabienne Eyquard ◽  
Martine Bonnouvrier ◽  
...  

Clinics ◽  
2020 ◽  
Vol 75 ◽  
Author(s):  
Liz Avlasevicius Oliveira ◽  
Magda Maria Sales Carneiro-Sampaio ◽  
Angela Midori Matuhara ◽  
Louise Cominato ◽  
Regina Celia Turola Passos Juliani ◽  
...  

Author(s):  
Grégoire Lagger ◽  
Jorge Cesar Correia ◽  
Peter Fernandes ◽  
Frédéric Sittarame ◽  
Alain Golay

Introduction: Type 2 diabetes (T2D) reversal has been demonstrated in patients undergoing bariatric surgery or low caloric diets. Objective: To investigate the effects of therapeutic patient education alone on T2D reversal in early diagnosed patients. Methods: Seventeen T2D patients underwent a one-week therapeutic education program, followed by 12 months of 1 hour sessions every month, targeting diabetes reversal. This reversal was determined using the DiaRem score which integrates glycated hemoglobin levels and antidiabetic drug treatment. Patient’s conceptions, perceptions and motivation were assessed using a 5-dimensional psychopedagogic score. Results: After 1 year, the mean HbA1C fell from 7.2% (± 1.9) to 6.2% (± 0.8) (p < 0.05), antidiabetic drug doses decreased by 25% (p < 0.05), and the DiaRem score increased by 15% (p < 0.01), indicating a reversal of the disease, not correlated to weight loss. At the end of the study, 15 out of 17 patients had excellent glycemic control (HbA1C < 7.0%) and 4 patients had parameters compatible with partial diabetes remission. A significant improvement in glycemic control coupled with a lowering of antidiabetic drug treatment was observed. Conclusions: Following an initial therapeutic education program and regular consultation sessions thereafter, early diagnosed patients may reverse their type 2 diabetes.


2020 ◽  
Vol 9 (10) ◽  
pp. 3106
Author(s):  
Anne Jenneve ◽  
Noel Lorenzo-Villalba ◽  
Guy Courdier ◽  
Samy Talha ◽  
François Séverac ◽  
...  

This study sought to determine whether the implementation of regular and structured follow-up of patients with chronic heart failure (CHF), combined with therapeutic education and remote monitoring solution, leads to better management. This was a single-center retrospective study conducted in a cohort of patients with proven CHF who were followed up in the Mulhouse region (France) between January 2016 and December 2017 by the Unité de Suivi des Patients Insuffisants Cardiaques (USICAR) unit. These patients received regular protocolized follow-up, a therapeutic education program, and several used a telemedicine platform for a two-year period. The primary endpoint was the number of days hospitalized for heart failure (HF) per patient per year. The main secondary endpoints included the number of days hospitalized for a heart condition other than HF and the number of hospital stays for HF per patient. These endpoints were collected during the year preceding enrollment, at one year of follow-up, and at two years of follow-up. The remote monitoring solution was evaluated on the same criterion. Overall, 159 patients with a mean age of 72.9 years were included in this study. They all had CHF, mainly NYHA Class I-II (88.7%), predominantly of ischemic origin (50.9%), and with altered left ventricular ejection fraction in 69.2% of cases. The mean number of days hospitalized for HF per patient per year was 8.33 (6.84–10.13) in the year preceding enrollment, 2.6 (1.51–4.47) at one year of follow-up, and 2.82 at two years of follow-up (1.30–6.11) (p < 0.01 for both comparisons). The mean number of days hospitalized for a heart condition other than HF was 1.73 (1.16–2.6), 1.81 (1.04–3.16), and 1.32 (0.57–3.08), respectively (p = ns). The percentage of hospitalization for HF for each patient was 69.5% (60.2–77.4), 16.2% (10–25.2), and 19.3% (11–31.8), respectively (p < 0.001 for both comparisons). In the group telemedicine, the mean number of days hospitalized for HF per patient per year was 8.33 during the year preceding enrollment, 2.3 during the first year of follow-up, and 1.7 during the second. This difference was significant (p < 0.001). The “number of days hospitalized for a heart condition other than HF” was significantly reduced in the group of patient’s beneficiating from the remote monitoring solution. This study demonstrates the value of a protocolized follow-up associated with a therapeutic optimization, therapeutic education program, and the use of a remote monitoring solution to improve the management of ambulatory patients with CHF, particularly of moderate severity.


Author(s):  
Carme Hernandez Carcereny ◽  
Nuria Seijas ◽  
Ana Folch ◽  
Mariana Roman ◽  
Isabel Orts ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document